Welcome to our dedicated page for Lifevantage SEC filings (Ticker: LFVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching for LifeVantage Corp’s latest consultant counts or product-line revenue without wading through dense text? Investors typically arrive here asking, “Where can I find LifeVantage’s quarterly earnings report 10-Q filing?” or “How do I track LifeVantage insider trading Form 4 transactions in real time?” This page bundles every SEC disclosure so you no longer jump between scattered EDGAR links.
Stock Titan’s AI reads each LifeVantage 8-K, 10-Q, and 10-K the moment it posts, then delivers plain-English summaries that flag shifts in independent-consultant enrollment, inventory risk and regulatory updates around nutrigenomic claims. Instead of skimming 200-plus pages, you’ll see the numbers that shape margins—net sales by product family, commission expense trends and emerging compliance issues—explained simply.
Use our quick-access tiles to drill into:
- Annual report 10-K simplified – pick out segment revenue, R&D on nutrigenomics and direct-sales compensation disclosures in minutes.
- Quarterly earnings report 10-Q – monitor consultant turnover, inventory levels and cash flow each quarter with AI-annotated highlights.
- Form 4 insider transactions – real-time alerts on LifeVantage executive stock moves so you can spot buying or selling trends fast.
- 8-K material events explained – leadership changes, product-safety notices or distributor policy updates distilled into key takeaways.
- Proxy statement executive compensation – understand how bonuses tie to enrolment growth and nutrigenomic product launches.
Whether you’re comparing quarters, dissecting compensation plans, or simply trying to “understand LifeVantage SEC documents with AI,” this hub keeps every filing current and comprehensible. Save hours, gain clarity, and turn regulatory disclosures into actionable insight.
LifeVantage (LFVN)51,330 shares and adds 16,491 performance RSUs granted on August 26, 2025. The original reported 40,336 shares and omitted this PRSU grant.
It also lists 3,750 PRSUs granted on December 23, 2024. Vesting for the 2024 grant: 50% on August 31, 2025; 30% on August 31, 2026; 20% on August 31, 2027, subject to performance and continued service. The 2025 grant vests 34% on September 10, 2026; 33% on September 10, 2027; and 33% on September 10, 2028. The amendment adds Exhibit 24, Power of Attorney.
Lifevantage (LFVN) disclosed the initial insider holdings of its Chief Information Officer. The officer directly owns 40,336 shares of common stock and holds 3,750 performance restricted stock units (PRSUs) at target eligibility.
The PRSUs were granted on December 23, 2024 and vest only upon achievement of specified financial performance criteria: 50% vested on August 31, 2025, with 30% scheduled for August 31, 2026 and 20% on August 31, 2027. Upon maximum performance achievement, up to 200% of the target number of units may be earned.
Kristen Cunningham, Chief Sales Officer and director at Lifevantage Corp (LFVN), reported an insider sale on 10/01/2025. The filing shows she sold 1,720 shares of Lifevantage common stock at a price of $9.56 per share, leaving her with 136,986 shares owned directly. The Form 4 was signed by a power of attorney on 10/03/2025. This report discloses a routine officer sale and the resulting post-transaction ownership.
Alissa Neufeld, who identifies her role as General Counsel of Lifevantage Corp (LFVN), reported a sale of 1,283 shares of the company's common stock on 10/01/2025 at a reported price of $9.56 per share. After the transaction the filing shows Ms. Neufeld beneficially owns 116,977 shares. The Form 4 is signed and dated 10/03/2025, indicating timely disclosure under Section 16 reporting requirements.
On 10/01/2025 Steven R. Fife, who is listed as President and CEO and a Director of Lifevantage Corp (LFVN), reported a sale of 8,181 shares of the company's common stock at a price of $9.56 per share. After the reported transaction, Mr. Fife's beneficial ownership is listed as 752,820 shares. The Form 4 was signed by a power of attorney on 10/03/2025.
Lifevantage Corp insider Carl Aure, the company's Chief Financial Officer, reported a sale of 1,361 shares of Common Stock on 10/01/2025 at a price of $9.56 per share. The Form 4 shows 159,969 shares remained beneficially owned by Mr. Aure after the transaction. The filing was signed by Alissa Neufeld as Power of Attorney on 10/03/2025.
Julie Boyster, listed as the Chief Marketing Officer of Lifevantage Corp (LFVN), reported a sale of company common stock on 10/01/2025. The Form 4 shows she disposed of 1,835 shares at a price of $9.56 per share. After the transaction she beneficially owned 150,088 shares, held directly. The filing was signed by a power of attorney on 10/03/2025. The form is a standard Section 16 filing reporting insider changes in beneficial ownership and contains no additional remarks or derivative transactions.
The Capital Management Corporation reported beneficial ownership of 2,064,176 shares of LifeVantage Corporation common stock, representing 16.3% of the class. The filing shows the filer has sole voting power over 2,041,176 shares and sole dispositive power over 2,064,176 shares. The statement is filed on a Schedule 13G/A for the reporting period ending September 30, 2025 and includes a signed certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. Contact and registration details identify Pamela C. Simms as Compliance Officer for The Capital Management Corporation, organized in Virginia.
LifeVantage Corporation is asking shareholders to vote on four routine proposals at its annual meeting, including election of seven directors and approval of an amendment to its 2017 Long-Term Incentive Plan that would add 400,000 shares to the reserve and extend the plan term to December 5, 2031. As of the Record Date, 12,691,009 shares were outstanding. The Board reports 71,500 option shares and 811,576 restricted stock/RSU awards outstanding under the plan and states 1,152,619 shares are available assuming maximum performance or 1,460,207 shares assuming target performance. The company reports a fair market stock price of $10.68 on the Record Date and estimates potential dilution would rise from 18.5% to 21.6% if the amendment is approved. The proxy describes executive pay structure changes (more PRSUs versus RSUs), recent dividend increases totaling $2.1M, and share repurchases of $3.1M (about 0.3M shares).
Darwin Lewis, a director of Lifevantage Corp (LFVN), reported an automatic purchase of common stock under a Rule 10b5-1 trading plan. On 09/16/2025 he acquired 450 shares at a price of $10.8499 per share, bringing his total beneficial ownership to 117,217 shares. The filing states the 10b5-1 plan was adopted on February 10, 2025. The Form 4 was signed on behalf of Mr. Lewis by a power of attorney on 09/18/2025. The report lists the transaction as a non-derivative acquisition and identifies Mr. Lewis as a director of the issuer.